Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Boehringer Ingelheim
Boehringer Ingelheim
Seeking Ofev successor, Boehringer takes PDE4B drug into phase 3
Pharmaphorum
Thu, 10/27/22 - 10:41 am
Boehringer Ingelheim
BI 1015550
IPH
Boehringer and Surrozen Seek Retinal Therapies Along the Wnt Pathway
BioSpace
Fri, 10/7/22 - 10:39 am
Boehringer Ingelheim
Surrozen
Wnt pathway
retinal diseases
R&D
Boehringer Ingelheim preps FDA submission with new data in rare pediatric lung disease
Endpoints
Tue, 09/6/22 - 05:00 pm
Boehringer Ingelheim
nintedanib
Ofev
Boehringer reports Phase III data for nintedanib in interstitial lung disease
Clinical Trials Arena
Tue, 09/6/22 - 10:45 am
Boehringer Ingelheim
clinical trials
nintedanib
interstitial lung disease
Boehringer Ingelheim finally has skin in the game, scoring its first dermatology FDA nod
Fierce Pharma
Fri, 09/2/22 - 12:19 pm
Boehringer Ingelheim
FDA
dermatology
GPP
Spevigo
In damage control mode, Perrigo clarifies that it's off the hook in key Zantac case
Fierce Pharma
Thu, 08/18/22 - 11:18 pm
Perrigo
Boehringer Ingelheim
GSK
legal
Zantac
Boehringer takes on antimicrobial resistance with Evotec, bioMérieux JV
Pharmaforum
Wed, 07/6/22 - 11:00 am
Boehringer Ingelheim
Evotec
Biomerieux
antimicrobial resistance
antibiotic resistance
Aurobac Therapeutics
Biopharma Investment in China is Thriving Amid U.S. Downturn
BioSpace
Tue, 07/5/22 - 11:52 pm
China
biotech
WuXi Biologics
Boehringer Ingelheim
Siemens Healthineers
AstraZeneca
Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers
BioSpace
Tue, 06/28/22 - 10:40 am
Boehringer Ingelheim
BiomX
biomarkers
microbiome
IBD
Boehringer Ingelheim to incubate biotechs with Hong Kong R&D leader
Endpoints
Fri, 06/17/22 - 09:51 am
Boehringer Ingelheim
R&D
Hong Kong
incubators
Boehringer Ingelheim Signs Option to Acquire Immunology Partner, Trutino Biosciences
BioSpace
Wed, 06/15/22 - 10:56 am
Boehringer Ingelheim
Trutino Biosciences
M&A
cancer
ASCO 2022 – the spirit of Rova-T struggles to live on
EP Vantage
Tue, 06/7/22 - 10:19 am
ASCO 2022
Rova-T
AbbVie
Harpoon Therapeutics
Amgen
Boehringer Ingelheim
Boehringer Ingelheim inks deal for targeted cancer antibodies from Singapore research org
Endpoints
Fri, 06/3/22 - 10:54 am
Boehringer Ingelheim
oncology
cancer
Singapore
R&D
Boehringer OKs $100M biobucks deal for hearing loss R&D project
Fierce Biotech
Wed, 04/13/22 - 10:38 am
Boehringer Ingelheim
hearing loss
Autigen
biobucks
Boehringer Ingelheim boosts R&D commitment, promises up to 15 new product launches by 2025
Endpoints
Tue, 04/5/22 - 11:31 pm
Boehringer Ingelheim
R&D
Lilly, BI-Partnered Kidney Trial Stopped Early Due to Positive Results
BioSpace
Wed, 03/16/22 - 11:20 pm
Eli Lilly
Boehringer Ingelheim
clinical trials
chronic kidney disease
empagliflozin
Eli Lilly, Boehringer Ingelheim's Jardiance turns up heat on AstraZeneca's Farxiga with broad EU heart failure approval
Fierce Pharma
Mon, 03/7/22 - 10:10 am
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
Europe
AstraZeneca
Farxiga
Boehringer backs AI-powered anti-infective startup ArrePath
Pharmaforum
Mon, 03/7/22 - 09:57 am
Boehringer Ingelheim
machine learning
artificial intelligence
ArrePath
anti-infectives
funding
Eli Lilly, Boehringer Ingelheim's Jardiance clinches heart failure edge with FDA nod for wider label
Fierce Pharma
Fri, 02/25/22 - 10:24 am
Eli Lilly
Boehringer Ingelheim
Jardiance
heart failure
FDA
Boehringer secures FDA’s Breakthrough Therapy Designation for oral therapy
Pharmaceutical Business Review
Fri, 02/25/22 - 09:58 am
Boehringer Ingelheim
idiopathic pulmonary fibrosis
FDA
BI 1015550
breakthrough status
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »